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Background and Aims: Pro-inflammatory signalling in the liver promotes the 
appearance of a metabolic phenotype that involves the transition from mitochondrial 
respiration to aerobic glycolysis. It was demonstrated that this metabolic shift occurs 
during the transition from healthy and early stage of liver injury (NAFLD/NASH, ALD 
to late stage of disease (i.e. cirrhosis), and further escalates during HCC 
development [1,2]. This metabolic signature enables dividing cells to satisfy anabolic 
and energetic needs for biomass production and to suppress apoptotic signalling, 
which is consistent with increased compensatory hepatic cell proliferation typical of 
cirrhotic and HCC livers. However other studies in contrast have suggested that 
hepatocytes are unable to sustain glycolysis during late stage of chronic liver disease 
[3].  
Methods: We used unbiased gene expression analyses of microarray datasets to 
investigate the expression of glycolytic genes in cirrhotic and HCC livers and 
correlated their expression with patient outcome. Furthermore, by using a 
combination of in vitro and in vivo analyses we have characterized the abilities of a 
novel anti-apoptotic gene to regulate aerobic glycolysis in liver cirrhosis and HCC.  
Results: mRNA profiling showed significantly higher expression of glycolytic 
transcripts in cirrhotic and HCC livers compared to normal quiescent livers (P<0.05). 
Up regulation of Glut1, Hk1, Hk2, G6PI, and PFKL was seen in HCC livers compared 
to their adjacent non-tumor tissues (P<0.001). Notably, expression of enzymes 
regulating mitochondrial activity (Pdha, Pdk) was unchanged between non-tumor 
tissues and late stage of HCC. Moreover, up regulation of a novel anti-apoptotic 
gene positively correlated with increased expression of glycolytic transcripts in a 
group of cirrhotic patients prospectively classified as poor prognosis based on HCC 
development, and promotes the aerobic glycolysis of hepatoma cells. 
Conclusions: In summary, our findings delineate a putative link between aerobic 
glycolysis and suppression of apoptosis that is an important part of the progression 
of cirrhosis to HCC. The identification of the mechanism regulating this link may lead 
to design new therapeutic strategies for human liver disease. 
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